Cytosorbents’ (CTSO) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital restated their buy rating on shares of Cytosorbents (NASDAQ:CTSO) in a research report sent to investors on Monday morning,Benzinga reports. The firm currently has a $10.00 target price on the medical research company’s stock.

Several other equities analysts have also recently weighed in on CTSO. StockNews.com initiated coverage on shares of Cytosorbents in a research note on Monday. They set a “hold” rating for the company. HC Wainwright reaffirmed a “neutral” rating and issued a $1.00 target price on shares of Cytosorbents in a research report on Monday, November 11th. Two research analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $4.67.

Cytosorbents Stock Up 3.8 %

CTSO stock opened at $1.08 on Monday. The company has a debt-to-equity ratio of 1.06, a current ratio of 1.97 and a quick ratio of 1.58. The stock has a market capitalization of $59.05 million, a P/E ratio of -3.00 and a beta of 0.58. Cytosorbents has a fifty-two week low of $0.70 and a fifty-two week high of $1.59. The business has a 50-day moving average of $0.92 and a 200-day moving average of $1.03.

Institutional Trading of Cytosorbents

A number of large investors have recently added to or reduced their stakes in CTSO. Atomi Financial Group Inc. acquired a new stake in Cytosorbents in the 3rd quarter valued at about $51,000. Geode Capital Management LLC boosted its stake in Cytosorbents by 7.5% in the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after purchasing an additional 32,415 shares during the period. Finally, Sargent Investment Group LLC increased its position in Cytosorbents by 4.9% during the 2nd quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company’s stock worth $1,008,000 after buying an additional 67,181 shares during the period. Institutional investors and hedge funds own 32.87% of the company’s stock.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.